GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

MIRA Pharmaceuticals MIRA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.62

+8.50%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About MIRA Pharmaceuticals

From its filings with the US Securities and Exchange Commission

SEC filings

MIRA Pharmaceuticals is based in Miami, Florida and is incorporated in Florida. Its shares trade on Nasdaq under the ticker MIRA. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $10.4m. At that date it held total assets of $11.1m and shareholders' equity of $10.4m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
3 Aug 2023
Employees
1
Head office
1200 BRICKELL AVENUE, MIAMI, FL, 33131
Incorporated in
FL
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Mr. Erez AminovChairman of the Board, Chief Executive Officer, since 2023$1.7m
  • Mr. Alan WeichselbaumChief Financial Officer
  • Dr. Denil ShekhatDirector$117,400
  • Dr. Matthew Del GiudiceIndependent Director$69,775
  • Mr. Edward MacphersonIndependent Director$69,775
  • Mr. Matthew WhalenIndependent Director$16,525

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • MIRA Pharmaceuticals Inc has a single full-time employee.
  • The company has completed an IPO on 2023-08-03.
  • MIRA1a is a synthetic cannabinoid analog targeting CB1 and CB2 receptors.

Weaknesses

  • The company employs only one full-time employee.
  • MIRA Pharmaceuticals operates as a clinical development stage biopharmaceutical company.
  • The company's product candidate MIRA1a is still in development.

Opportunities

  • MIRA1a targets neuropsychiatric, inflammatory, and neurologic diseases and disorders.
  • The company focuses on treating anxiety and cognitive decline associated with early-stage dementia.
  • MIRA1a aims to balance THC and CBD effects for anxiety and chronic pain treatment.

Threats

  • MIRA Pharmaceuticals is a clinical development stage company with no commercialized products.
  • The company's product candidate MIRA1a is still in development phase.
  • The pharmaceutical industry faces high regulatory and development risks.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.